$ 5
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of ACHV is 16 and suggests 228% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
